AbClon Inc operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares AbClon Inc with three other
companies in this sector in KOREA (SOUTH) :
Helixmith Co Ltd
sales of 4.30 billion Korean Won [US$3.85 million]
of which 436%
was Drug Medicine Research and Development),
Ensol Biosciences Inc
(588.45 million Korean Won [US$526,664.97 ]
of which 100%
was Pharmaceutical Development and Sales), and
(3.12 billion Korean Won [US$2.79 million]
of which 54%
During the first
quarter of 2021, sales at AbClon Inc totalled
568.34 million Korean Won .
This is a drop of 33.7%
from the 857.17 million Korean Won in sales at the company during the first quarter in 2020.
Sales fell dramatically in 2020:
AbClon Inc reported sales of 2.77 billion Korean Won (US$2.48 million)
December of 2020.
decrease of 80.7%
versus 2019, when the company's sales were 14.38 billion Korean Won .
Contributing to the drop in overall sales was the 96.8% decline
in Royalty, from 11.50 billion Korean Won to 363.75 million Korean Won .
There were also decreases in sales in
Service (down 24.0% to 1.58 billion Korean Won )
However, these declines were partially offset by the increase in sales of
Merchandise (up 3.8% to 831.19 million Korean Won )